Favoritar este trabajo
¿Cómo citar este artículo?
Resúmenes

As a part of Medicines for Malaria Venture’s efforts to deliver a clinical candidate that could be used as a Single Encounter Radical Cure and Prophylaxis (SERCaP) for Malaria, several compound libraries were screened against Plasmodium falciparum. The Screening Actives were prioritized based on their potency, physicochemical properties, and structural alerts. Then, top prioritized compounds were resynthesized or purchased to confirm the activity against P falciparum.
Once the activity of the Screening Actives is confirmed, the Hit Compounds are profiled in depth, to prioritize work on series that are more likely to progress to Lead Optimization Stage. For instance, throughout our work we found that besides testing the compounds against sensitive and resistant strains, we should also evaluate the propensity of generating resistance by determining the Minimum Inoculum for Resistance. Herein, we will present some of our progress towards the Validation of Hit Compounds.

¡Comparte tus ideas o preguntas con los autores!

¿Sabías que el mayor estímulo en el desarrollo científico y cultural es la curiosidad? ¡Deje sus preguntas o sugerencias al autor!

Inicia sesión para interactuar

¿Tiene alguna pregunta o sugerencia? ¡Comparte tus comentarios con los autores!

Instituciones
  • 1 UNICAMP
  • 2 Medicines for Malaria Venture
  • 3 Universidade Estadual de Campinas
  • 4 USP - São Carlos
  • 5 Universidade de São Paulo
  • 6 MMV
Eje Temático
  • 2. Medicinal Chemistry of Synthetic Compounds
Palabras Clave
Drug Discovery
Drug Development
hit validation
malária
SAR exploration